January 11, 2025
On January 10th, 2025, BOCG's portfolio company, Ribo Life Science, with its subsidiary, Ribocure Pharmaceuticals AB, announced that they have achieved a key pre-clinical milestone in their siRNA programs, less than a year into their collaboration with Boehringer Ingelheim with an overall deal value that exceeds USD 2 billion.
December 20, 2024
On December 6, 2024, the 7th Venture Capital Responsible Investment Forum was successfully held in Lujiazui, Shanghai. Frank Yang, Founding Partner and CEO of BOCG, was invited to join the roundtable discussion on “Healthcare Innovation and Well-Being”, engaging in in-depth dialogue with fellow participants.
October 29, 2024
Recently, BOCG's portfolio company, Ribo Life Science, announces that it received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the lipid-lowering siRNA drug RBD5044 that targets APOC3.
September 20, 2024
On September 11, 2024, the Hong Kong International Biotechnology Convention (BIOHK2024) was grandly opened. Frank Yang, Founding Partner & CEO of BOCG, was honored to join distinguished experts from the fields of investment, entrepreneurship, and medicine for a panel discussion on the theme, “Can Biotech Be Hong Kong’s Next Pillar of Growth?”
September 12, 2024
On September 10th, the 2024 Shenzhen Biomedical Industry Investment and Promotion Conference was successfully held. BOCG’s portfolio companies, Boan Biotech and Ribo Life Science, participated in the signing ceremony as partners, announcing their intent to establish a presence in Shenzhen. Frank Yang, Founding Partner and CEO of BOCG, was interviewed by several media outlets, sharing his insights on Shenzhen’s unique advantages and prospects for developing the biomedical industry as an innovative city in the Greater Bay Area.
July 24, 2024
Recently, BOCG's portfolio company, Innorna, announces that China National Medical Products Administration (NMPA) has granted a Drug Clinical Trial Approval Notice for its self-developed Herpes Zoster (HZ) mRNA vaccine IN001; meanwhile, U.S. FDA orphan drug designation granted to IN022 for the Treatment of Homocystinuria after it was granted rare pediatric disease designatio.
July 17, 2024
On July 12, 2024, Mr. Frank Yang, founding partner & CEO of Blue Ocean Capital Group, was invited by the HK Bio-Med Innotech Association and the Hong Kong Productivity Council to lecture in Hong Kong for entrepreneurs, scientists, and managers in the biopharmaceutical industry.
